



TPE 2024 | Education

Fortify Your Future

**Industry Overview: The
Path Ahead**

Regulations

Flavors

Products

- FDA-CTP authorization
- MRTP

Illicit trade

Business

Products

- Flavors
- Menthol
- Enforcement

Economics

Risk Management

Innovation

Operating Environment

Legal issues

Politics

Other recreational molecules

Cigarettes

Cigars

ENDS

Oral

White Pouches
et. al.

State & local actions (bans)

5 states (MA, NJ, NY, RI, CA) & Nearly 400 localities in 12 states

FDA-CTP final rule on product standards

(menthol cigarettes & flavored cigars)

- March 2024 (???)*
- Mitigating factors

*HHS FY 2023 Unified Regulatory Agenda: [View Rule \(reginfo.gov\)](https://www.reginfo.gov)

CTP product authorization

- No flavor other than tobacco authorized under PMTA alone
- High authorization standard

A little too quiet?

- Avoided trigger points to spur CTP action
- Full agenda – next target?
- Acceptable off-ramp in the absence of any other flavored products?

Synthetic nicotine

Products: by the numbers

Source: <https://www.fda.gov/tobacco-products/substantial-equivalence/marketing-orders-se>



PMTA's since 2021:

278

Companies with Vape/ENDS products in-market received Marketing Denial Orders from CTP equaling millions of individual SKUs

4

Companies (Logic, Reynolds, NJOY, & US Smokeless Tobacco CO.) received Marketing Granted Orders for non-traditional nicotine products

1

Brand (Verve) was authorized for market with a characterizing flavor

SE's* since 2021:

**FDA tracking extends only to the end of FY 2022*

11

Cigarette SE submissions gained authorization

40

Cigar SE submissions gained authorization

144

Pipe product SE submissions gained authorization

8

RYO product SE submissions gained authorization

11

Hookah product SE submissions gained authorization

Modified Risk Tobacco Product: what is it?

Risk or exposure modification claim authorized to be made about the product

PMTA required as first step

Time-bound up to 5 years, then needs renewal

Proven to be a difficult process

In action, there are significant questions about its commercial viability

Only instance where a manufacturer can make a statement on risk & a product

Counterfeits, Tax Avoidance, Trade in Unauthorized Products

Multiple Pathways of
Market Penetration:


- DTC
- DTR or DTW

Inflows from Asia
(flavored ENDS and
counterfeits)


Inflows from S. America
(tax avoidance)

3 authorized ENDS
brands (Logic, NJOY,
Vuse) and an unknown
number of provisionally
authorized brands, all
unflavored, cannot
counterbalance against
a large and lucrative
market of unauthorized
products.


US Cigarette Volumes 2012-2021




Nicotine Users in the U.S. (2021)




Total 18+ Population Nicotine Users (2021)



Nicotine Consumer Socioeconomic Indicators (2021)



Prevailing economic conditions, especially inflation, will be a deciding factor in 2024





United States

Preauthorization is both a focus of and a constraint upon innovation

- Creates barriers to entry for new products
- Capital intensively of innovation vis-à-vis preauthorization drive consolidation of innovation:
 - Capital access and operational scale
 - Product evolution
 - Market entry
 - Number of actors
- Mismatch of products to consumer preferences (performance & illicit concerns)

Globally

Combination of consumer driven & regulatory driven innovation

- Action on disposable products
- Heated products:
 - Different markets & consumers
- More straightforward route to market
- More licit players and products (greater opportunity)
- Similar concerns to the US:
 - Regulatory action on flavors
 - Youth issues
 - Illicit trade

- **Circuit splits in deciding MDO legal challenges**
 - **Product standards (?)**
 - **Public health (?)**



The 2024 election will inject further uncertainty into not only the political but also regulatory process. Perhaps the effects are manifesting themselves already.



2016–2020 was an extraordinarily challenging time for the industry:

- EVALI crisis
- FDA actions
- International trade

Other molecules used as active ingredients used in adult recreational products will continue to face an uncertain road. It is highly unlikely, given the dynamics, that comprehensive policy decisions at the federal level will be forthcoming.

Whilst there is progress at other levels of government on normalization, the continued ambiguities at the federal level are likely to persist throughout the year and into 2025.

The similarities between these products and vape are striking.